From the financial report:
ARC Linkage Grant to Develop Drugs Targeting a Novel Cancer Target: The University of Queensland, with Phylogica as a commercial collaborator, was awarded a prestigious ARC linkage grant of $546,420 to develop drugs against a novel cancer target. This project will focus on another transcription factor called SOX18, which acts as a master regulator controlling the spread of cancer throughout the body.
...............................
I found some additional info on this grant: ARC Linkage Grants
..............................
LP140100798 Gambin, Dr Yann; Hopkins, Dr Richard; Watt, Adj/Prof Paul M; Francois, Dr Mathias F
2014 $63,494.00
2015 $168,352.00
2016 $209,716.00
2017 $104,858.00
Total $546,420.00
Primary FoR 1101 MEDICAL BIOCHEMISTRY AND METABOLOMICS
Partner Organisation(s) Phylogica Limited
Administering Organisation The University of Queensland
Project Summary
This project aims at expanding the pool of drug targets, by extending drug screening to protein-protein interaction networks. This project aims to assemble a novel technical platform to detect binding between proteins, using a combination of cell-free protein expression, AlphaScreen and single-molecule fluorescence. This pipeline has great potential to accelerate the exploration of protein networks, and provides also a generic platform for drug screening on difficult targets. The project intends to screen Phylogica's libraries of peptides called Phylomers to discover tight binders to a Transcription Factor, Sox18. The objective of this project is to determine which Phylomers can disrupt specific interactions between Sox18 and its binding partners involved in lymphangiogenesis.
.........................
Cheers
SoT
PYC Price at posting:
1.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)